Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomised, parallel-group comparison to investigate the efficacy of Yasmin (30 microg ethinylestradiol, 3mg drospirenone) and Marvelon (30 microg ethinylestradiol, 150 microg desogestrel) on cycle control in healthy Chinese women over 13 cycles

Next Previous
X
Search
Trial Profile

An open-label, randomised, parallel-group comparison to investigate the efficacy of Yasmin (30 microg ethinylestradiol, 3mg drospirenone) and Marvelon (30 microg ethinylestradiol, 150 microg desogestrel) on cycle control in healthy Chinese women over 13 cycles

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Drospirenone/ethinylestradiol (Primary) ; Ethinylestradiol/desogestrel
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Sponsors Bayer

    • Most Recent Events

    • 13 Jan 2009 Additional trial identifier 91330 reported by ClinicalTrials.gov.
    • 13 Jan 2009 Planned patient number added (842) as reported by ClinicalTrials.gov.
    • 13 Jan 2009 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top